BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)
Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –
BioMarin Pharmaceutical cash
Cash and short-term investments held at the end of each period.
BioMarin Pharmaceutical's cash was $874.01M at Jun 30, 2026. For fiscal 2025 it was $1.56B, up 37.2% from the year before. Over ten years it grew 10.2% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | +37.2% |
| FY2024 | Dec 31, 2024 | $1.14B | +6.0% |
| FY2023 | Dec 31, 2023 | $1.07B | -16.9% |
| FY2022 | Dec 31, 2022 | $1.29B | +27.4% |
| FY2021 | Dec 31, 2021 | $1.01B | -4.8% |
| FY2020 | Dec 31, 2020 | $1.07B | +41.3% |
| FY2019 | Dec 31, 2019 | $753.81M | -30.5% |
| FY2018 | Dec 31, 2018 | $1.08B | -22.3% |
| FY2017 | Dec 31, 2017 | $1.40B | +76.8% |
| FY2016 | Dec 31, 2016 | $789.68M | +33.3% |
| FY2015 | Dec 31, 2015 | $592.62M | -37.3% |
| FY2014 | Dec 31, 2014 | $945.19M | +20.4% |
| FY2013 | Dec 31, 2013 | $784.72M | +75.2% |
| FY2012 | Dec 31, 2012 | $447.81M | +129.5% |
| FY2011 | Dec 31, 2011 | $195.09M | -28.8% |
| FY2010 | Dec 31, 2010 | $274.11M | -8.8% |
| FY2009 | Dec 31, 2009 | $300.68M | +34.9% |
| FY2008 | Dec 31, 2008 | $222.90M | -2.4% |
| FY2007 | Dec 31, 2007 | $228.34M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $874.01M | -39.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.22B | +74.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.56B | +37.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.48B | +58.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.43B | +17.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.27B | +21.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.14B | +6.0% |
| Q3 FY2024 | Sep 30, 2024 | $930.44M | -17.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.22B | +4.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.05B | -9.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.07B | -16.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.13B | -11.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.17B | +5.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.15B | +9.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.29B | +27.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.27B | +18.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.11B | -1.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.06B | -2.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.01B | -4.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.08B | -28.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.12B | -18.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.09B | +26.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.07B | +41.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.51B | +108.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.38B | +88.8% |
| Q1 FY2020 | Mar 31, 2020 | $858.40M | -4.1% |
| Q4 FY2019 | Dec 31, 2019 | $753.81M | -30.5% |
| Q3 FY2019 | Sep 30, 2019 | $720.79M | -50.1% |
| Q2 FY2019 | Jun 30, 2019 | $731.10M | -46.4% |
| Q1 FY2019 | Mar 31, 2019 | $894.85M | -35.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.08B | -22.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.44B | +14.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.36B | +87.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.38B | +103.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.40B | +76.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.26B | +21.5% |
| Q2 FY2017 | Jun 30, 2017 | $727.78M | – |
| Q1 FY2017 | Mar 31, 2017 | $678.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $789.68M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.03B | – |
See a number that looks wrong?